Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
YAZ is an oral contraceptive tablet approved by the FDA in 2007 and sponsored by Bayer. The product treats contraception and potentially other gynecological indications through hormonal mechanisms. It represents a small-molecule oral formulation in the contraceptive market.
Product is in late-stage lifecycle with minimal Part D penetration, signaling a mature, stable franchise requiring defensive positioning rather than growth investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea
YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China
To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea
Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
Worked on YAZ at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moYAZ presents limited career expansion opportunities given zero linked job openings and approaching loss of exclusivity. Roles available are primarily defensive/maintenance-focused, focused on protecting market share against generics and competing branded alternatives rather than driving growth.